Progress and prospect on imaging diagnosis of COVID-19

Li Fan1 · Dong Li2 · Huadan Xue3 · Longjiang Zhang4 · Zaiyi Liu5 · Bing Zhang6 · Lina Zhang7 · Wenjie Yang8 · 
Baojun Xie9 · Xiaoyi Duan10 · Xiuhua Hu11 · Kailiang Cheng12 · Liqing Peng13 · Nan Yu14 · Lan Song3 · Huai Chen15 · 
Xin Sui3 · Nannan Zheng16 · Shiyuan Liu1 · Zhengyu Jin3

Received: 23 February 2020 / Revised: 23 February 2020 / Accepted: 4 March 2020 / Published online: 18 March 2020
© Springer Nature Singapore Pte Ltd. 2020

Abstract COVID-19 has become a public health emergency due to its rapid transmission. The appearance of pneumonia is one of the major clues for the diagnosis, progress and therapeutic evaluation. More and more literatures about imaging manifestations and related research have been reported. In order to know about the progress and prospective on imaging of COVID-19, this review focus on interpreting the CT findings, stating the potential pathological basis, proposing the challenge of patients with underlying diseases, differentiating with other diseases and suggesting the future research and clinical directions, which would be helpful for the radiologists in the clinical practice and research.

Keywords COVID-19 · Imaging · Viral pneumonia · Artificial intelligence
Introduction

In early December 2019, a series of viral pneumonia cases of unknown cause emerged in Wuhan, Hubei, China [1]. This virus is a novel type of the coronavirus family, which is named 2019 novel coronavirus (2019-nCoV) by the World Health Organization (WHO) in January 7, 2020. The 2019-nCoV will cause acute respiratory system infections, and is called coronavirus disease 19 (COVID-19). The WHO has recently declared the COVID-19 a public health emergency of international concern, because of rapid spread from Wuhan to the entire China as well as many other countries [2].

Due to its highly contagious clinical feature, rapid and reliable diagnosis of COVID-19 is very important. It can not only guide the follow-up therapies to improve outcomes, but also help to control the disease spread effectively. Chest CT is one of the key components in the diagnostic work-up for patients with suspected infection.

In this pictorial review, we focus on interpreting the CT findings, stating the potential pathological basis, proposing the challenge of patients with underlying diseases, differentiating with other diseases and suggesting the future research and clinical directions.

Clinical features and diagnosis criteria

Clinical features

The infection source is mainly the COVID-19 patients with or without symptoms. The main routes of transmission are respiratory droplets and close contact. 2019-nCoV is highly infectious with high incidence of susceptibility crowd. According to the current epidemiological data, the mean incubation period of COVID-19 is 3 days (0–24 days) [3]. The main clinical symptoms are fever (87.9%) and cough (67.7%). Some mild patients show no symptoms. Serious ill patients may present with dyspnea and hypoxemia about 1 week after onset of initial symptoms, even aggravate as acute respiratory distress syndrome (ARDS), septic shock, refractory metabolic acidosis, et al.

On admission, 82.1% and 33.7% patients had lymphopenia and leukopenia, respectively. The elevated level of C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were observed. Severe cases had more prominent laboratory abnormalities (i.e., lymphopenia, leukopenia, elevated C-reactive protein levels) as compared with non-severe cases [3]. The nucleic acid of 2019-nCoV can be detected in respiratory secretions, blood, and stool specimen, which is the evidence of definite diagnosis.

Diagnosis criteria

According to Diagnosis and Treatment Protocols of COVID-19 Infection (6th edition) (hereafter referred to as Protocols-Ver6) issued by the National Health Commission of the People’s Republic of China, in February 19, 2020 [4], the diagnosis of COVID-19 should be decided by epidemiological, clinical and laboratory characteristics comprehensively.

Epidemiological histories include: (1) travel history or residence history in and around Wuhan City no earlier than 14 days before initial symptoms onset; (2) close contact history with COVID-19 patients no earlier than 14 days before initial symptoms onset; (3) contact history with patients with fever or respiratory symptoms from Wuhan City and its surrounding area no earlier than 14 days before initial symptoms onset; (4) clustering occurrence.

Clinical manifestations include: (1) fever and/or respiratory symptoms; (2) the imaging findings of COVID-19 pneumonia; (3) reduced/normal total WBC count, or reduced lymphocyte count.

Suspended cases should have both one of the epidemiological histories and two of the clinical manifestations, or have three of the clinical manifestations without epidemiological history. If the nucleic acid of 2019-nCoV in samples of respiratory tract and blood was detected in suspended case by using reverse transcription polymerase chain reaction (RT-PCR) technique, then the final diagnosis should be issued.

The detection rate of nucleic acid with RT-PCR is influenced by many factors and the reaction itself is time consuming. Considering the large amounts of patients with epidemiological histories and typical clinical manifestations in Hubei Province, suspended cases with typical imaging findings would be considered as clinically diagnosed cases in Protocols-Ver5. This is only applicable in special period, and the has Protocols-Ver6 has deleted it from the diagnosis criteria. In some extent, this represents the outbreak leveling off at the release time of Protocols-Ver6.

Clinical category

According to the Protocols-Ver6 [4], COVID-19 is divided into mild type, moderate type, severe type and critical type based on its severity. (1) Mild type, clinical symptoms are mild, and no pneumonia appearance was found in imaging; (2) moderate type, with fever, respiratory symptom or others, and pneumonia appearance was found in imaging; (3) severe type, with any of the followings, respiratory distress, RR ≥ 30 times/min; oxygen saturation ≤ 93% in resting state; arterial partial pressure of oxygen (PaO2)/concentration of
oxygen (FiO₂) ≤ 300 mmHg; fast progression on imaging findings (more than 50%) within 24–48 h; (4) critical type, with any of the followings, respiratory failure, mechanical ventilation, shock and other organ failure resulting in the treatment in the Intensive Care Unit (ICU).

**Imaging manifestation of COVID-19**

**Imaging technique**

Chest X-ray is the most convenient and economic modality for the screening and follow up of most pulmonary diseases. However, since the early imaging manifestation of COVID-19 is ground glass opacity (GGO), which could be missed by chest X-ray due to its low-resolution nature and projection overlapping. Therefore, CT is recommended for the screening of COVID-19, while chest X-ray, especially the bedside X-ray, plays an important role in the follow-up of the severe and critical cases [5]. High resolution CT is the best choice to detect possible pulmonary opacities in COVID-19 suspicious patient. At present, low dose CT is not recommended for the screening of COVID-19 due to the low imaging quality and possibility of false negative GGO detection.

**CT findings**

COVID-19 CT findings vary with the patient's age, immunity status, disease stage, underlying diseases and drug interventions at the time of scanning [6]. In the largest cohort (n = 1099) study by Guan et al. [3], 23.6% confirmed cases with CT scanning (n = 840) showed no pneumonia on CT images (Fig. 1).

According to the published data [7–20], the imaging manifestations of COVID-19 are somewhat overlapping with other viral pneumonia, especially SARS, which belongs to the same viral family. According to the reported patient cohorts, the most typical chest CT findings in patients with COVID-19 include unilateral or bilateral, focal, multifocal, or diffuse areas of GGO and consolidation with subpleural, peripheral or peribronchovascular distribution [7–15]. GGO superimposed the thickening of interlobular or intralobular septa manifest as ‘crazy-paving’ sign. Several atypical features have been reported as well, including halo sign, reversed halo sign (the atoll sign), cavity, small pleural effusion, pneumothorax, and lymphadenopathy [16–18]. Over time and following treatment, findings of fibrosis, including architectural distortion, traction bronchiectasis and peribronchovascular thickening may be seen. The following aspects should be evaluated comprehensively to make the diagnosis in combination with the epidemiological, clinical and laboratory characteristics.

1. **Distribution pattern**

   The distribution of the pulmonary disease depends on the pathogenesis. The most frequent distribution is subpleural or peripheral area (86%, 44/51) [18] (Figs. 2, 3). Moreover, the lower lobe (53%) and posterior lung (89%) is more prone to be involved [19]. Occasionally, inner zone of lung can be affected (Fig. 4). Peri-bronchovascular bundle thickening can be found (Fig. 5).

2. **Quantity and range**

   Some cases show uni-focal lesion as the initial CT finding, then multifocal with the disease progression; while some show multifocal lesions at onset. 71% (15/21) patients had involvement of at least two lobes [20]; 63% (32/51) patients involved four to five lobes [19] (Fig. 6).

3. **Density**

   The density of lesion is usually heterogeneous. GGO is the most common imaging feature, presenting in about 50% (550/1099) cases. Consolidation (37.2%, 409/1099) [3], GGO with consolidation (59%, 30/51) [19], and fibrosis [12] can occur in severe type cases (Fig. 7). The first pathological findings of COVID-19 by postmortem biopsy showed the bilateral diffuse alveolar damage with cellular fibromyxoid exudate, which is the basis of GGO and consolidation [21].
4. Shape and interface

The shape is related to the distribution pattern. Common shapes include patchy, cone-shape or triangle, subsegmental, and segmental. Sometimes, round or centrilobular nodule with halo sign [17] or reversed halo sign [18] also can be seen. The interface between lesion and the normal pulmonary is often ill-defined. Occasionally, the mosaic perfusion may be present (Figs. 8, 9, 10, 11, 12, 13).

Fig. 3 Male, 51 years. A history of travel to Wuhan in the last 2 weeks, fever, cough, decreased WBC and lymphocyte count, elevated CRP. CT shows bilateral, multiple and subpleural GGO and consolidation

Fig. 4 Male, 66 years. A history of travel to Wuhan in the last 2 weeks, fever, cough, decreased WBC and lymphocyte count, elevated CRP and LDH. CT shows multiple GGO with subpleural and peribronchovascular distribution, involvement of the inner zone of right middle lobe

Fig. 5 Male, 68 years. Cluster transmission, fever, cough, normal WBC, decreased lymphocyte count, and elevated CRP. CT shows multiple GGO with peribronchovascular distribution and sparing the pleural surface

Fig. 6 Male, 50 years. A history of travel to Wuhan in the last 2 weeks, fever, cough, short breath, hypoxemia, normal WBC, decreased lymphocyte count, and elevated CRP and LDH. CT shows multiple GGO involvement of five lobes

Fig. 7 Male, 41 years. A history of travel to Wuhan in the last 2 weeks, fever, cough, decreased WBC lymphocyte count, elevated CRP. CT shows multiple consolidation, GGO, and AB sign

Fig. 8 Male, 40 years. A history of travel to Wuhan in the last 2 weeks, no fever, no cough, normal WBC, decreased lymphocyte count, elevated CRP and ESR. CT shows multiple patchy, ill-defined consolidation, GGO, thickening of intralobular septa and fibrosis. AB sign and mosaic perfusion was seen
Halo sign is defined as a circle of GGO surrounding a soft tissue density lung nodule, may be seen in some patients with a solitary pulmonary nodule. The histologic nature of halo varies with the disease, such as the hemorrhage, and lipid spread of tumor. The halo sign in patients with COVID-19 may be caused by the alveolar edema and hemorrhage. While reversed-halo sign may be related to the organization and resolution of alveolar exudates.

5. Internal feature in the lesion

The typical and most common internal features are ‘crazy-paving’ sign (GGO superimposed the thickening of interlobular or intralobular septa), thickening of small vessels with natural course, and air bronchogram (AB) (80%, 41/51). Sometimes, bronchovascular bundle
is thickened within the lesion. Cavity can occur in occasion [16] (Figs. 14, 15, 16).

6. Adjacent structures changes

The common changes of adjacent structures include the thickening and/or shifting of pleural (Fig. 17). The subpleural region may be spared (Fig. 18) or not [22], speculating related to the amount of alveolar exudates and the distance to the pleural. Pleural effusion, pericardial effusion and lymphadenopathy are rare.

**CT staging system**

CT staging system is important to evaluate the disease progress and evolution. In general, CT staging system is based on the pathological change, the combination of CT findings and pathological features could provide more accurate information. The first CT staging system was reported by Shi H, in which COVID-19 CT findings is classified into early stage, progressive stage and severe stage [7]. Then, taking clinical manifestation and pathologic changes into account, Jin proposed a five-stages system which include ultra-early stage, early stage, rapid progression stage, consolidation stage and dissipation stage [6]. The first CT staging system is based on the imaging findings alone; while the second one is mainly based on the days of symptom onset. In practice, the imaging findings and clinical symptoms may not match. Therefore, the most optimized CT staging system should be based on the evolution of pathology.

**Quantitative CT and AI**

CT findings of COVID-19 depend heavily on its disease severity. It has been reported that CT quantitation of pneumonia in the severe and critical type was significantly higher than that of moderate type [8]. The ratio of pneumonia volume to the entire lungs can be used as a quantitative parameter of disease severity evaluation. The quantitative evaluation of pneumonia volume has been defined as an important indicator for management of the severe type patients. Several AI assistant diagnosis systems have already being developed and are being tested in hospitals currently, focusing on the intelligent scanning, diagnosis and severity evaluation, in order to minimize the contact transmission, improve the diagnostic accuracy and guide the treatment.
Imaging outcome and dynamic change during follow up

The evolution process of COVID-19 on CT image is not quite clear yet. Feng et al. [23] reviewed 21 patients recovering from COVID-19 (without severe respiratory distress during the disease course). The mean interval between baseline and follow-up CT scans was $4 \pm 1$ days, and the mean hospitalization duration was $17 \pm 4$ days. The majority of cases with COVID-19 were controlled with stable and improving conditions after effective personalized treatment. The peak severity was at approximately 10 days and the improvement happened at approximately 14 days after initial onset of symptoms. The follow-up CT showed that the lesions in lungs were decreased in both number and size. The density of lesions was reduced as well [12, 24]. The CT findings of clinically cured cases showed full recovery or only small amounts of residual stripes (Fig. 19). For some cases, the GGO and consolidation in lungs became some thick fibrotic stripes in short term, which need follow-up studies to explore its final outcome.

Some cases with COVID-19 failed to receive effective therapy will reach their deterioration and the changes will be rather rapid. The lesions on CT will become more diffuse distributed in a truly short-term [25].

Imaging presentation of COVID-19 in Children

Most children cases with COVID-19 are characterized as family cluster disease. The symptoms in children with COVID-19 are mild and the prognosis is very good. The nucleic acid of 2019-nCoV should be examined with anal swab, which is more sensitive than throat swab in children.

Chest X-ray may show no abnormality, therefore it is not recommended as a screening tool in children. CT findings of COVID-19 in children were variable and non-specific.

The GGO and consolidation were also the most common findings in bilateral lungs, while the lesions in children were less diffused than adults [25]. One relative specific CT characteristics in children was the presentation mimic bronchopneumonia. Pleural effusion and lymphadenopathy were also not observed (Fig. 20).

For suspicious children cases, CT findings can help to setup treatment plan in time, as well as patient isolation to avoid further contamination. While, the final diagnosis should be confirmed by laboratory examination (PCR).

COVID-19 complicated with underlying disease

Common underlying diseases include chronic obstructive pulmonary disease, diabetes, hypertension, coronary heart disease, cerebrovascular diseases, hepatitis B infection, cancer, chronic renal diseases, immunodeficiency, hematopathy, et al. The largest cohort study showed that 25.2% (255/1099) patients coexisted at least one underlying disease, and the ratio of underlying cases in severe group was significantly higher than that in non-severe group (38.2% vs. 22.5%, $P < 0.001$) [3]. Patients with underlying disease may result in more severe COVID-19 [1], there is yet no literatures later showed the consolidation were smaller in size and the GGO became diffused. The follow-up CT 16 days later showed consolidation and GGO were resolved instead of fibrous strips.

Fig. 19 Female, 62 years. From Wuhan, fever for 5 days, normal WBC and decreased lymphocyte count, elevated CRP and PCT. The CT obtained at first day after admission showed bilateral, multiple and subpleural GGO and consolidation. The follow-up CT 3 days later showed the consolidation were smaller in size and the GGO became diffused. The follow-up CT 16 days later showed consolidation and GGO were resolved instead of fibrous strips.
about the COVID-19 imaging manifestation in patients with underlying pulmonary diseases. Patients with potential disease, especially for immunodeficiency, are more prone for the infection, especially the viral infection [26, 27]. In clinical practice, the differential diagnosis should include the disease associated with the underlying disease. The imaging features of patients with underlying disease should be accumulated and investigated.

**Differential diagnosis**

The differential diagnosis between COVID-19 and other pulmonary infection and/or non-infectious disease is very important but also very difficult due to its overlapping imaging features. The epidemiological history, clinical symptoms, laboratory and imaging manifestations should be considered comprehensively before diagnosis is reached. But the confirmed diagnosis should be based on the etiology eventually. Although definitive diagnosis cannot be made on the basis of imaging features alone, the imaging patterns may help to improve the accuracy of diagnosis in this disease. According to the imaging findings of COVID-19 summarized by the current confirmed cases, it should be differentiated with other viral pneumonia, bacterial pneumonia, mycoplasmal pneumonia as well as many non-infectious diseases.

**Other viral pneumonia**

Imaging patterns can help to identify the viral pathogens. Viruses in the same viral family share a similar pathogenesis of pneumonia, and the imaging patterns have distinguishable characteristics for the entire viral family. The spectrum of CT findings can be classified into five categories: (a) parenchymal attenuation disturbances; (b) ground glass opacity and consolidation; (c) nodules, micronodules, and tree-in-bud opacities; (d) interlobular septal thickening; and (e) bronchial and/or bronchiolar wall thickening [28]. Some selected viral pneumonias including influenza, respiratory syncytial virus (RSV), adenovirus, and coronavirus are discussed below.

**Influenza viruses** are members of the Orthomyxoviridae family. They can be divided into three groups (A, B, and C) according to the internal membrane and nucleoprotein antigens [29]. Influenza (A) are more common in infancy, while often mild and restricted to the upper respiratory tract in immunocompetent adults. In recent years, influenza virus has been reported as a major cause of pneumonia in immunocompromised patients. The pathogenesis is the destruction of airway epithelial barrier, resulting in necrotizing bronchitis and diffuse alveolar damage [30]. The predominant CT findings are unilateral or bilateral ground-glass opacities with or without associated focal or multifocal areas of consolidation, with the predominant peribronchovascular and subpleural distribution.

RSV is the most frequent viral cause of lower respiratory tract infection in infants [31]. The pathogenesis is the destruction of bronchial and alveolar epithelium with small airway obstruction, and the typical CT findings are multiple centrilobular nodules and bronchial wall thickening [29].

**Adenovirus** accounts for 5–10% of acute respiratory infections in infants and children [32]. Meanwhile, it is also a common cause in immunocompromised individuals, especially stem cell and solid organ transplant recipients. The pathogenesis is the bronchiolar and alveolar damage. The radiographic manifestations are multifocal consolidation in a lobular or segmental distribution and/or bilateral ground-glass opacities with a random distribution [33]. Lobar collapse, especially of the right upper lobe is common in children [28].

**Coronaviruses** include severe acute respiratory syndrome coronavirus (SARS) and Middle East respiratory syndrome coronavirus (MERS), which were outbroken in 2003 and 2012 respectively [34, 35]. COVID-19 also belongs to this viral family. Therefore, their pathogenesis and imaging presentations were quite similar. SARS manifested as unilateral or bilateral ground-glass opacities, consolidation, thickening of the intralobular interstitium or interlobular septa and a crazy-paving appearance due to diffuse alveolar damage. Cavitation, lymphadenopathy, and pleural effusion are rare [36]. MERS pneumonia appears as subpleural and basilar airspace lesions, with extensive GGO. Consolidation is relatively rare in MERS, while more common in COVID-19. Crazing-paving appearance is usually with the distortion of pulmonary architecture in SARS in comparison with COVID-19. Pleural effusion and pneumothorax are more common in MERS [37].

**Bacterial pneumonia**

Streptococcus pneumonia is the most common cause of pneumonia associated with Gram-positive cocci [27]. Typical clinical symptoms consist of abrupt onset of high fever, rusty brown sputum, shaking chills and chest pain. CT images show the unilateral or bilateral, lobar or segment consolidation, extending to pleural surfaces. And the air bronchogram and pleural effusion is very common.

**Mycoplasmal pneumonia**

Mycoplasma pneumonia is a common cause of community-acquired pneumonia, and mostly occurs in young patients.
The most common pathogenesis is the direct cytotoxicity and damage incurred from the host inflammatory response [38]. The clinical symptoms are similar with those of viral infection, such as dry cough, fever, and malaise. The CT images manifest as patchy, segmental, and lobular consolidation or ground glass opacity, and sometimes showing the thickening of perihilar interstitium, which is different from the COVID-19.

Non-infectious diseases

Until now, GGO is one of the major CT findings of COVID-19. Some non-infectious diseases, such as interstitial pulmonary edema, hypersensitivity pneumonitis, and alveolar proteinosis, manifest as GGO. Patients with interstitial pulmonary edema usually have the definite clinical history, and the corresponding CT images show the smooth interlobular septal thickening, thickening of the peribronchovascular interstitium and GGO. Hypersensitivity pneumonitis is an allergic lung disease caused by exposure to the antigen. The typical CT imaging show patchy GGO and small ill-defined centrilobular GGN. The clinical symptoms, known exposure to antigen and GGO on CT can make the clinical diagnosis. The typical CT findings of alveolar proteinosis include the bilateral areas of GGO, smooth interlobular septal thickening, consolidation, and geographic distribution [38].

Conclusion

CT imaging findings cannot be used as gold-standard of COVID-19 diagnosis due to its overlapping and non-specific features with many other pulmonary diseases. However, it still plays a great role in detecting pneumonia existence, assessing disease progression as well as monitoring treatment response. COVID-19 imaging manifestation in patients with underlying diseases has not been investigated comprehensively. Moreover, multicenter study including the epidemiological, clinical and laboratory characteristics, and imaging should be performed to improve the diagnosis, guide the treatment and accelerate the implementation of isolation measures, then control the transmission.

Acknowledgements We appreciate the contribution of Drs. Jiong Ni (Tongji Hospital, Tongji University School of Medicine), Weimei Chen (Tongji hospital, Tongji Medical college, Huazhong University of Science and Technology), Jianhong Chen (Beijing Friendship Hospital Capital Medical University), Junping Zhen (The Second Hospital of Shanxi Medical University), Miao Chang (The First Affiliated Hospital of China Medical University), Xiaodan Ye (Shanghai Chest Hospital, Shanghai Jiaotong University), and Zhigang Chu (The First Affiliated Hospital of Chongqing Medical University), who greatly facilitate the collection of patient’s CT data.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

References

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
2. WHO main website. https://www.who.int. Accessed 5 Feb 2020. https://doi.org/10.1073/pnas.1502972112.
3. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020. https://doi.org/10.1101/2020.02.06.20020974.
4. Diagnosis and Treatment Protocols of COVID-19 Infection (Trial Version 6). The National Health Commission of the People’s Republic of China.
5. Radiology CSo. Radiological diagnosis in novel coronavirus pneumonia: expert recommendation from the Chinese Society of Radiology (version 1). Chin J Radiol. 2020;54:E001-E. https://doi.org/10.3760/cma.j.issn.1005-1201.2020.0001.
6. Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. https://doi.org/10.1186/s40779-020-0233-6.
7. Shi H, Han X, Fan Y, et al. Radiologic features of patients with 2019-nCoV infection. J Clin Radiol. 2020. https://doi.org/10.13437/j.cnki.jcr.20200206.002.
8. Huang LHR, Yu P, et al. The correlation between clinical characteristics and CT findings in different clinical stage in COVID-19. Chin J Radiol. 2020;54(00):E003. https://doi.org/10.3760/cma.j.issn.1005-1201.2020.0003 (in Chinese).
9. Liu P, Tan X-z. Novel coronavirus (2019-nCoV) pneumonia. Radiology. 2019;2020:200257. https://doi.org/10.1148/radiol.2020200257.
10. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. Radiology. 2020;2020:200241. https://doi.org/10.1148/radiol.12020020241.
11. Xie X, Zhong Z, Zhao W, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020;2020:200343. https://doi.org/10.1148/radiol.2020200343.
12. Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. 2020;2020:200269. https://doi.org/10.1148/radiol.2020200269.
13. Qian L, Yu J, Shi H. Severe acute respiratory disease in a Huanan seafood market worker: images of an early casualty. Radiol Cardiothorac Imaging. 2020;2(1):e200033. https://doi.org/10.1148/ryct.2020200033.
14. Liu T, Huang P, Liu H, et al. Spectrum of chest CT findings in a familial cluster of COVID-19 infection. Radiol Cardiotorhac Imaging. 2020;2(1):e200025. https://doi.org/10.1148/ryct.2020200025.
15. Huang P, Liu T, Huang L, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 2020;2020:200330. https://doi.org/10.1148/radiol.2020200330.
16. Kong W, Agarwal PP. Chest imaging appearance of COVID-19 infection. Radiol Cardiothorac Imaging. 2020;2(1):e200028. https://doi.org/10.1148/ryct.2020200028.

17. Li X, Zeng X, Liu B, et al. COVID-19 infection presenting with CT Halo sign. Radiol Cardiothorac Imaging. 2020;2(1):e200026. https://doi.org/10.1148/ryct.2020200026.

18. Fang Y, Zhang H, Xu Y, et al. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;2020:200280. https://doi.org/10.1148/radiol.2020200280.

19. Song F, Shi N, Shan F, et al. Emerging coronavirus-2019-nCoV pneumonia. Radiology. 2020;2020:200274. https://doi.org/10.1148/radiol.2020200274.

20. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;2020:200230. https://doi.org/10.1148/radiol.2020200230.

21. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30076-X.

22. Lei J, Li J, Li X, et al. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;2020:200236. https://doi.org/10.1148/radiol.2020200236.

23. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020;2020:200370. https://doi.org/10.1148/radiol.2020200370.

24. Duan Y-N, Qin J. Pre- and posttreatment chest CT findings: 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;2020:200323. https://doi.org/10.1148/radiol.2020200323.

25. Jiang N, Zheng C, Fan Y, et al. CT appearance of new coronavirus pneumonia in subclinical period and short-term changes. Chin J Radiol. 2020;54:E008-E. https://doi.org/10.3760/cma.j.issn.1005-1201.2020.0008 (in Chinese).

26. Choi MH, Jung JI, Chung WD, et al. Acute pulmonary complications in patients with hematologic malignancies. RadioGraphics. 2014;34(6):1755–68. https://doi.org/10.1148/rg.346130107.

27. Garg M, Prabhakar N, Gulati A, et al. Spectrum of imaging findings in pulmonary infections. Part 1: bacterial and viral. Pol J Radiol. 2019;84:e205-e13. https://doi.org/10.5114/pjr.2019.85812.

28. Franquet T. Imaging of pulmonary viral pneumonia. Radiology. 2011;260(1):18–39. https://doi.org/10.1148/radiol.11092149.

29. Koo HJ, Lim S, Choe J, et al. Radiographic and CT features of viral pneumonia. RadioGraphics. 2018;38(3):719–39. https://doi.org/10.1148/rg.2018170048.

30. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3(1):499–522. https://doi.org/10.1146/annurev.pathmechdis.3.121806.154316.

31. Sinaniotis CA. Viral pneumonias in children: incidence and aetiology. Paediatr Respir Rev. 2004;5:5197–200. https://doi.org/10.1016/S1526-0542(04)90037-1.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.